| Literature DB >> 32489451 |
Song Chen1, Yun Yang2, Ziyi Luo3, Haiqing Deng4, Tiancheng Peng1, Zhongqiang Guo1.
Abstract
Objective: To explore the independent risk factors of infection during the intravesical instillation of bladder cancer and establish a prediction model, which may reduce probability of infection for bladder cancer patients. Material andEntities:
Keywords: Bladder cancer; Infection; Intravesical instillation; Prediction model; TURBT
Year: 2020 PMID: 32489451 PMCID: PMC7255357 DOI: 10.7150/jca.45055
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
Clinical characteristics of enrolled patients in the development cohort.
| Variables | Zhongnan Hospital (n=396) | Renmin Hospital (n=137) | |
|---|---|---|---|
| 0.523 | |||
| Average/Median (Range) | 66.1 ± 11.6/66 | 66.7 ± 10.4/67 | |
| 47 - 86 | 49 - 86 | ||
| 0.146 | |||
| Male | 272 (68.7) | 99 (72.3) | |
| Female | 124 (31.3) | 38 (27.7) | |
| 0.908 | |||
| No | 312 (78.8) | 105 (76.6) | |
| Yes | 84 (21.2) | 32 (23.4) | |
| 0.852 | |||
| No | 366 (92.4) | 132 (96.4) | |
| Yes | 30 (7.6) | 5 (3.6) | |
| 0.790 | |||
| <1 | 259 (65.4) | 94 (68.6) | |
| ≥1 | 137 (34.6) | 43 (31.4) | |
| 0.664 | |||
| Vesical trigone | 110 (27.8) | 43 (31.4) | |
| Sidewall | 119 (30.1) | 39 (28.5) | |
| Anterior and posterior wall | 125 (31.6) | 42 (30.7) | |
| Others | 42 (10.6) | 13 (9.5) | |
| 0.715 | |||
| <2 | 207 (52.3) | 68 (49.6) | |
| ≥2 | 189 (47.7) | 69 (50.4) | |
| 0.589 | |||
| Ta -T1 | 332 (83.8) | 123 (89.8) | |
| T2-T4 | 64 (16.2) | 14 (10.2) | |
| 0.814 | |||
| G1 | 193 (48.7) | 75 (54.7) | |
| G2 | 161 (40.7) | 52 (38.0) | |
| G3 | 42 (10.6) | 10 (7.3) | |
| 0.167 | |||
| No | 138 (34.8) | 35 (25.5) | |
| Yes | 258 (65.2) | 102 (74.5) | |
| 0.392 | |||
| <2 times/month | 177 (44.7) | 68 (49.6) | |
| ≥2 times/month | 219 (55.3) | 69 (50.4) | |
| 0.618 | |||
| Gemcitabine | 214 (54.0) | 80 (58.4) | |
| BCG | 48 (12.1) | 20 (14.6) | |
| Hydroxycamptothecin | 60 (15.2) | 15 (10.9) | |
| Epirubicin | 40 (10.1) | 17 (12.4) | |
| Others | 34 (8.6) | 5 (3.6) |
Clinical characteristics of infection during the intravesical instillation of BCa patients.
| Variables | All patients (n=533) | Infection negative (n=348) | Infection positive (n=185) | |
|---|---|---|---|---|
| 0.006 | ||||
| Average/Median (Range) | 66.3 ± 12.4/66 | 62.5 ± 11.6/63 | 71.1 ± 10.3/71 | |
| 47 - 86 | 47 - 81 | 52 - 86 | ||
| < 65 | 143 (26.8) | 111(31.9) | 32(17.3) | |
| ≥ 65 | 390 (73.2) | 237(68.1) | 153(82.7) | |
| 0.002 | ||||
| Male | 371 (69.6) | 296(85.1) | 75(40.5) | |
| Female | 162 (30.4) | 52(14.9) | 110(59.5) | |
| 0.011 | ||||
| No | 417 (78.2) | 291(83.6) | 126(68.1) | |
| Yes | 116 (21.8) | 57(16.4) | 59(31.9) | |
| 0.044 | ||||
| No | 498 (93.4) | 335(96.3) | 163(88.1) | |
| Yes | 35 (6.6) | 13(3.7) | 22(11.9) | |
| 0.039 | ||||
| <1 | 353 (66.2) | 252(72.4) | 101(54.6) | |
| ≥1 | 180 (33.8) | 96(27.6) | 84(45.4) | |
| 0.250 | ||||
| Vesical trigone | 153 (28.7) | 92(26.4) | 61(33.0) | |
| Sidewall | 158 (29.6) | 93(26.7) | 65(35.1) | |
| Anterior and posterior wall | 167 (31.3) | 121(34.8) | 46(24.9) | |
| Others | 55 (10.3) | 42(12.1) | 13(7.0) | |
| 0.042 | ||||
| <2 | 275 (51.6) | 201(57.8) | 74(40.0) | |
| ≥2 | 258 (48.4) | 147(42.2) | 111(60.0) | |
| 0.731 | ||||
| Ta -T1 | 455 (85.4) | 291(83.6) | 164(88.6) | |
| T2-T4 | 78 (14.6) | 57(16.4) | 21(11.4) | |
| 0.705 | ||||
| G1 | 268 (50.3) | 169(48.6) | 99(53.5) | |
| G2 | 213 (40.0) | 138(39.7) | 75(40.5) | |
| G3 | 52 (9.8) | 41(11.8) | 11(5.9) | |
| 0.008 | ||||
| No | 173 (32.5) | 94(27.0) | 79(42.7) | |
| Yes | 360 (67.5) | 254(73.0) | 106(57.3) | |
| 0.023 | ||||
| <2 times/month | 245 (46.0) | 185(53.2) | 60(32.4) | |
| ≥2 times/month | 288 (54.0) | 163(46.8) | 125(67.6) | |
| 0.846 | ||||
| Gemcitabine | 294 (55.2) | 193(55.5) | 101(54.6) | |
| BCG | 68 (12.8) | 41(11.8) | 27(14.6) | |
| Hydroxycamptothecin | 75 (14.1) | 52(14.9) | 23(12.4) | |
| Epirubicin | 57 (10.7) | 38(10.9) | 19(10.3) | |
| Others | 39 (7.3) | 24(6.9) | 15(8.1) |
Pathogenic spectrum of patients with positive infection.
| Pathogenic bacteria | Cases | % |
|---|---|---|
| 67 | 36.2 | |
| 20 | 10.8 | |
| 28 | 15.1 | |
| 25 | 13.5 | |
| 12 | 6.5 | |
| 15 | 8.1 | |
| 6 | 3.2 | |
| 12 | 6.5 | |
| Total | 185 | 100% |
Univariate logistic analysis for infection during the intravesical instillation of BCa patients.
| Variables | OR | 95% CI | |
|---|---|---|---|
| 1.314 | 1.119 - 1.622 | 0.042 | |
| 1.267 | 1.107 - 1.381 | 0.036 | |
| 1.436 | 1.246 - 1.855 | 0.008 | |
| 2.115 | 1.967 - 2.662 | 0.002 | |
| 1.021 | 0.862 - 1.136 | 0.145 | |
| 1.132 | 0.934 - 1.219 | 0.103 | |
| 3.128 | 2.425 - 4.018 | < 0.001 | |
| 1.646 | 1.328 - 1.983 | 0.004 |
Multivariate logistic analysis for infection during the intravesical instillation of BCa patients.
| Variables | OR | 95% CI | |
|---|---|---|---|
| 1.381 | 1.181 - 1.685 | 0.009 | |
| 2.054 | 1.653 - 2.546 | 0.011 | |
| 3.223 | 2.520 - 4.148 | < 0.001 | |
| 1.819 | 1.412 - 2.037 | 0.003 |
Figure 1The nomogram for prediction model of infection during the intravesical instillation. To estimate the risk of infection, the points for each variable were calculated by drawing a straight line from a patient's variable value to the axis labelled “Points”. The score sum is converted to a probability in the lowest axis.
Figure 2The calibration curve developed for prediction model of infection during the intravesical instillation. The nomogram-predicted probability is plotted on the x-axis, and the actual probability is plotted on the y-axis.
Figure 3The ROC curves developed for prediction model of infection during the intravesical instillation. The AUC of infection prediction model was 0.858 (95%CI: 0.762-0.904).